BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 21880132)

  • 1. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.
    Velenik V; Ocvirk J; Music M; Bracko M; Anderluh F; Oblak I; Edhemovic I; Brecelj E; Kropivnik M; Omejc M
    Radiat Oncol; 2011 Aug; 6():105. PubMed ID: 21880132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
    Velenik V; Ocvirk J; Oblak I; Anderluh F
    Eur J Surg Oncol; 2010 Mar; 36(3):244-50. PubMed ID: 20042310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.
    Nogué M; Salud A; Vicente P; Arriví A; Roca JM; Losa F; Ponce J; Safont MJ; Guasch I; Moreno I; Ruiz A; Pericay C;
    Oncologist; 2011; 16(5):614-20. PubMed ID: 21467148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.
    Dellas K; Höhler T; Reese T; Würschmidt F; Engel E; Rödel C; Wagner W; Richter M; Arnold D; Dunst J
    Radiat Oncol; 2013 Apr; 8():90. PubMed ID: 23587311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.
    Zhu J; Gu W; Lian P; Sheng W; Cai G; Shi D; Cai S; Zhang Z
    Radiat Oncol; 2013 May; 8():130. PubMed ID: 23718210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.
    Crane CH; Eng C; Feig BW; Das P; Skibber JM; Chang GJ; Wolff RA; Krishnan S; Hamilton S; Janjan NA; Maru DM; Ellis LM; Rodriguez-Bigas MA
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):824-30. PubMed ID: 19464823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
    Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
    Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer.
    Koeberle D; Burkhard R; von Moos R; Winterhalder R; Hess V; Heitzmann F; Ruhstaller T; Terraciano L; Neuweiler J; Bieri G; Rust C; Toepfer M
    Br J Cancer; 2008 Apr; 98(7):1204-9. PubMed ID: 18349837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.
    Kennecke H; Berry S; Wong R; Zhou C; Tankel K; Easaw J; Rao S; Post J; Hay J
    Eur J Cancer; 2012 Jan; 48(1):37-45. PubMed ID: 21664123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer.
    Gasparini G; Torino F; Ueno T; Cascinu S; Troiani T; Ballestrero A; Berardi R; Shishido J; Yoshizawa A; Mori Y; Nagayama S; Morosini P; Toi M
    Angiogenesis; 2012 Mar; 15(1):141-50. PubMed ID: 22212406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
    Zhu J; Liu F; Gu W; Lian P; Sheng W; Xu J; Cai G; Shi D; Cai S; Zhang Z
    Radiat Oncol; 2014 Mar; 9():70. PubMed ID: 24606870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
    Willeke F; Horisberger K; Kraus-Tiefenbacher U; Wenz F; Leitner A; Hochhaus A; Grobholz R; Willer A; Kähler G; Post S; Hofheinz RD
    Br J Cancer; 2007 Mar; 96(6):912-7. PubMed ID: 17325705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer--a two stage phase II clinical trial.
    Resch G; De Vries A; Öfner D; Eisterer W; Rabl H; Jagoditsch M; Gnant M; Thaler J;
    Radiother Oncol; 2012 Jan; 102(1):10-3. PubMed ID: 21741716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant capecitabine, bevacizumab and radiotherapy for locally advanced rectal cancer: results of a single-institute Phase I study.
    Miki Y; Maeda K; Hosono M; Nagahara H; Hirakawa K; Shimatani Y; Tsutsumi S; Miki Y
    J Radiat Res; 2014 Nov; 55(6):1171-7. PubMed ID: 25129557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
    Ofner D; Devries AF; Schaberl-Moser R; Greil R; Rabl H; Tschmelitsch J; Zitt M; Kapp KS; Fastner G; Keil F; Eisterer W; Jäger R; Offner F; Gnant M; Thaler J;
    Strahlenther Onkol; 2011 Feb; 187(2):100-7. PubMed ID: 21267531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204.
    Landry JC; Feng Y; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Prabhu RS; Benson AB
    Cancer; 2013 Apr; 119(8):1521-7. PubMed ID: 23288663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.
    Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Inoue M; Kobayashi S; Tojima Y; Yoshioka Y; Nakayama G; Yatsuya H; Ohmiya N; Goto H; Nagino M
    Jpn J Clin Oncol; 2013 Oct; 43(10):964-71. PubMed ID: 23935207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer.
    Kim JS; Kim JS; Cho MJ; Song KS; Yoon WH
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):403-8. PubMed ID: 12243814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Velenik V; Anderluh F; Oblak I; Strojan P; Zakotnik B
    Croat Med J; 2006 Oct; 47(5):693-700. PubMed ID: 17042060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study.
    Koukourakis MI; Giatromanolaki A; Tsoutsou P; Lyratzopoulos N; Pitiakoudis M; Kouklakis G; Chloropoulou PA; Manolas K; Sivridis E
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):492-8. PubMed ID: 20584585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.